SCHEMBL4776141

SCHEMBL4776141

Cc1nc(Cl)c([N+](=O)[O-])c(NCCO)c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.43
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GAA P10253 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
MAPT P10636 7/20 0.39
NPC1 O15118 1/20 0.39
PKM P14618 1/20 0.39
ATM Q13315 1/20 0.38
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
ABCG2 Q9UNQ0 1/20 0.37
CDK5 Q00535 4/20 0.37
CDK5R1 Q15078 4/20 0.37
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
HIF1A Q16665 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4773953 0.95 POLB (0.40) POLBALDH1A1SMN1; SMN2GAATDP1
SCHEMBL3172845 0.92 POLB (0.42) POLBALDH1A1SMN1; SMN2GAATDP1
SCHEMBL4773797 0.91 POLB (0.41) POLBALDH1A1SMN1; SMN2GAATDP1
SCHEMBL4769171 0.89 POLB (0.40) POLBALDH1A1SMN1; SMN2GAATDP1
SCHEMBL4771569 0.89 POLB (0.40) POLBALDH1A1SMN1; SMN2GAATDP1
SCHEMBL13527456 0.88 POLB (0.42) POLBALDH1A1SMN1; SMN2GAATDP1
SCHEMBL4772531 0.87 POLB (0.41) POLBALDH1A1SMN1; SMN2GAATDP1
SCHEMBL4777754 0.83 MAPT (0.43) POLBALDH1A1SMN1; SMN2GAATDP1
SCHEMBL4775385 0.82 POLB (0.41) POLBALDH1A1SMN1; SMN2TDP1MAPT
SCHEMBL27614131 0.82 MAPT (0.43) POLBALDH1A1SMN1; SMN2TDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513524-A4 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES CO (US) 2008-09-03 EP disclosed
US-7220758-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-22 US disclosed
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2006-11-09 US disclosed
US-7125890-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-10-24 US disclosed
EP-1513524-A2 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2005-03-16 EP disclosed
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors 3M INNOVATIVE PROPERTIES COMPANY 2005-02-10 US disclosed
US-6797718-B2 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-09-28 US disclosed
US-20040010007-A1 Ether substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-01-15 US disclosed
WO-2003103584-A2 ETHER SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252792-A1 ETHER SUBSTITUTED IMIDAZOPYRIDINES IL2, IL4, MYD88 POLB 3686/4885ALDH1A1 1803/4885SMN1; SMN2 2887/4885
US-20050032830-A1 Immunology for viral diseases and biosynthesis of cytokines of anticancer drugs for tumors IL2, IFNG, TSLP POLB 3743/4885ALDH1A1 940/4885SMN1; SMN2 4130/4885
US-20040010007-A1 Ether substituted imidazopyridines IL2, IL4, MYD88 POLB 3686/4885ALDH1A1 1803/4885SMN1; SMN2 2887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.